- Home
- TXMD vs IDAI Comparison
TXMD vs IDAI Comparison
Compare TXMD & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | IDAI |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9M | 21.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TXMD | IDAI |
|---|---|---|
| Price | $2.49 | $3.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 121.4K | 87.3K |
| Earning Date | 03-26-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | $2,796,000.00 | ★ $3,727,824.00 |
| Revenue This Year | $427.09 | $3.46 |
| Revenue Next Year | N/A | $219.85 |
| P/E Ratio | $91.22 | ★ N/A |
| Revenue Growth | ★ 75.19 | 72.57 |
| 52 Week Low | $0.72 | $1.43 |
| 52 Week High | $2.95 | $5.28 |
Technical Indicators
Market Signals| Indicator | TXMD | IDAI |
|---|---|---|
| Relative Strength Index (RSI) | 56.50 | 43.14 |
| Support Level | $2.12 | $2.70 |
| Resistance Level | $2.54 | $3.59 |
| Average True Range (ATR) | 0.27 | 0.33 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 36.78 | 37.46 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.